Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the SAPIEN 3 Ultra system has received U.S. Food and Drug Administration (FDA) a
Ultra-low profile balloon expandable valve: Edwards SAPIEN 3 THVHendrik Treede
Edwards SAPIEN 3, Ultra 3 Transcatheter Heart Valve产品名称,P140031 S102申请号,pma申请类型,EDWARDS LIFESCIENCES, LLC.申请人,数据来源于药智数据美国上市器械数据库。
The instructions for use (IFU) for the Edwards SAPIEN 3 (S3) valve limit device implantation to patients with annular areas of <683 mm2. There are limited reports on the safety and efficacy of S3 use in patients with annular sizes larger than recommended in the IFU. Methods Among a total...
Edwards Higher Standard Brochure PP--US-5551 v3.0 Click to view in fullscreen Print Print All Pages Print Current Page Print Range Print
In these conditions, the possibility of implanting a biological prosthesis for TAVI, pre–mounted on the expansion balloon (Ewards–Sapien3–Ultra–23mm), in an "open" situation and in CEC, was considered. The implantation of the balloon–expandable prosthesis was performed with direct vision of...
John Webb
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve产品名称,P140031 S132申请号,pma申请类型,EDWARDS LIFESCIENCES, LLC.申请人,数据来源于药智数据美国上市器械数据库。
Newer-generation of Edwards transcatheter aortic valve systems: SAPIEN 3, Centera, and SAPIEN 3 Ultradoi:10.1080/17434440.2019.1555465Amir SolomonicaTawfiq ChoudhuryRodrigo BagurExpert Rev Med Devices
Edwards SAPIEN 3, SAPIEN 3 Ultra Transcatheter Heart Valves产品名称,P140031 S082申请号,pma申请类型,EDWARDS LIFESCIENCES, LLC.申请人,数据来源于药智数据美国上市器械数据库。